ClinicalTrials.gg
CompletedNCT04612517Updated Sep 2, 2021

A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

An Early Phase 1 interventional study of ZP7570 and Placebo in Healthy, sponsored by Zealand Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-02.

Sponsored by Zealand Pharma · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomised, double-blind, placebo-controlled, multiple ascending dose trial in healthy subjects, randomised to ZP7570 or placebo within each cohort

Read the detailed description

Forty subjects are planned to be studied in four cohorts in this multiple ascending dose trial. Ten subjects will be allocated to four dose levels. Intermediate dose levels may be applied. A sentinel dosing approach (sequential dosing) will be applied. The entire observation period comprises 51 days starting with a 96 hours in-house stay after the first dose injection, where discharge is planned for Day 5, followed by one outpatient visit. For the second and the third injection dose a 36 hours in-house stay is planned. After the fourth dose injection there is also a 96 hour in-house stay where discharge is planned for Day 26, followed by five outpatient visits and an End of Trial Visit on Day 51. A blinded evaluation of each cohort will be performed by a Trial Safety Group to determine whether the trial will progress to the next planned dose level based on the stopping rules specified in the protocol.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated obtained before any trial-related activities. Trial-related activities are any procedures that would not have been done during normal management of the subject.
  • Healthy male or female subject (only women not of ) aged between 18 and 55 years, both inclusive.
  • (BMI) between 18.5 and 28.0 kg/m2, both inclusive
  • A body weight of at least 60 kg.
  • Heart rate after 5 minutes rest in supine position inside the range of 50-90 beats/min at screening

Exclusion criteria

Exclusion Criteria:

  • Any history of a disorder which in the investigator's opinion might jeopardize subjects safety, evaluation of results or compliance with the protocol.
  • History of gallbladder disease or cholecystectomy.
  • History of pancreatitis
  • History of major depressive disorder or a Patient Health Questionnaire (PHQ-9) > 9 completed at screening, or a history of other severe psychiatric disorders (e.g. schizophrenia or bipolar disorder).
  • Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to screening.
  • Family history of multiple endocrinological neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC).
  • abnormal standard 12-lead after 5 min resting in supine position at screening, including a > 450 ms (males) or QTcF > 470 ms (females), PR ≥ 220 ms and QRS ≥ 110 ms.
  • History of severe to medicines or foods or history of severe medicinal/food induced anaphylactic reaction .
  • Any clinically significant abnormal hematology, biochemistry, or urinalysis screening tests, as judged by the investigator.
  • TSH values outside of normal reference ranges of safety laboratory
  • Estimated (eGFR) \< 90 ml/min/1.73 m2, as defined by - Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
  • Known or suspected hypersensitivity to IMP(s) or related products.
  • Systolic blood pressure \< 90 mmHg or >139 mmHg and/or diastolic blood pressure \< 50 mmHg or > 89 mmHg (one repeat test will be acceptable in case of suspected white-coat hypertension).
  • Symptoms of arterial hypotension
  • Women of
  • Men with non-pregnant partner(s) of childbearing potential not willing to use male (condom) in addition to a highly effective contraceptive method until 28 days after dosing
  • Men with pregnant partner not willing to use male contraception (condom) until 28 days after dosing, in order to avoid exposure of the embryo/fetus to seminal fluid.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    ZP7570

    Four ascending doses of ZP7570

    Drug: ZP7570

  • Placebo comparator
    Placebo

    Corresponding volume of placebo

    Drug: Placebo

Interventions

  • DrugZP7570

    Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.

    Also known as: Dual GLP-1R/GLP-2R agonist

  • DrugPlacebo

    Placebo; corresponding volume

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability - Incidence of treatment emergent adverse events as assessed by type and severity

    The incidence, type and severity of treatment emergent adverse events

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing) ]

Secondary outcomes

  1. Pharmacokinetics - Area under the plasma concentration-time curve - through

    AUCτ, Area under the plasma concentration-time curve from zero to through concentration.

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  2. Pharmacokinetics - Area under the plasma concentration-time curve - infinity

    AUCinf, Area under the plasma concentration-time curve from zero to infinity concentration.

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  3. Pharmacokinetics - Area under the plasma concentration-time curve - last

    AUClast, Area under the plasma concentration-time curve-from zero to last concentration.

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  4. Pharmacokinetics - Maximum plasma concentration - Cmax

    Cmax, Measured maximum plasma drug concentration after dosing

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  5. Pharmacokinetics - Time to maximum plasma concentration - Tmax

    Tmax, Sampling time until reaching Cmax after dosing

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  6. Pharmacokinetics - Elimination rate constant - λz

    λz, Elimination rate constant

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  7. Pharmacokinetics - Half-life - t½

    t½, Half-life of ZP7570

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  8. Pharmacokinetics - Volume of distribution - Vz/f

    Vz/f, Apparent volume of distribution of ZP7570 during terminal phase

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  9. Pharmacokinetics - Body clearance - CL/f

    CL/f, Apparent total body clearance

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  10. Pharmacokinetics - Mean residence time - MRT

    MRT, Mean residence time

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  11. Pharmacodynamics - Acetaminophen concentration-time curves

    Acetaminophen concentration-time curves following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose

  12. Pharmacodynamics - Maximum acetaminophen concentration - Cmax

    Cmax, maximum acetaminophen concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose

  13. Pharmacodynamics - Time to maximum acetaminophen concentration - Tmax

    Tmax, Time to maximum acetaminophen concentration following ingestion of mixed meal test and acetaminophene

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  14. Pharmacodynamics - Area under the concentration-time curve - AUCacetaminohen,0-60min

    AUCacetaminohen,0-60min, area under the acetaminophen concentration-time curve from 0 to 60 min post-ingestion

    Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose

  15. Pharmacodynamics - Area under the concentration-time curve - AUCacetaminohen,0-240min

    AUCacetaminohen,0-240min, area under the acetaminophen concentration -time curve from 0 to 240 min post-ingestion

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  16. Pharmacodynamics - Plasma glucose concentration-time curves

    Plasma glucose concentration-time curves following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose

  17. Pharmacodynamics - Maximum plasma glucose concentration - Cmax

    Cmax, Maximum plasma glucose concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose

  18. Pharmacodynamics - Time to maximum plasma glucose concentration - Tmax

    Tmax, Time to maximum plasma glucose concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  19. Pharmacodynamics - Area under the concentration-time curve - AUCplasma glucose,0-60min

    AUCplasma glucose,0-60min, area under the plasma glucose concentration-time curve from 0 to 60 min post-ingestion

    Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  20. Pharmacodynamics - Area under the concentration-time curve - AUCplasma glucose,0-240min

    AUCplasma glucose,0-240min, area under the acetaminophen concentration -time curve from 0 to 240 min post-ingestion

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  21. Pharmacodynamics - Insulin concentration-time curves

    Insulin concentration-time curves following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  22. Pharmacodynamics - Maximum insulin concentration - Cmax

    Cmax, Maximum insulin concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  23. Pharmacodynamics - Time to maximum insulin concentration - Tmax

    Tmax, Time to maximum insulin concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  24. Pharmacodynamics - Area under the concentration-time curve - AUCinsulin,0-60min

    AUCinsulin,0-60min, area under the insulin concentration-time curve from 0 to 60 min post-ingestion

    Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  25. Pharmacodynamics - Area under the concentration-time curve - AUCinsulin, 0-240min

    AUCinsulin,0-240min, area under the insulin concentration-time curve from 0 to 240 min post-ingestion

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  26. Pharmacodynamics - Glucagon concentration-time curves (optional)

    Glucagon concentration-time curves following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  27. Pharmacodynamics - Maximum glucagon concentration - Cmax (optional)

    Cmax, Maximum glucagon concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  28. Pharmacodynamics - Time to maximum glucagon concentration - Tmax (optional)

    Tmax, Time to maximum glucagon concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  29. Pharmacodynamics - Area under the concentration-time curve - AUCglucagon,0-60min (optional)

    AUCglucagon,0-60min, area under the glucagon concentration-time curve from 0 to 60 min post-ingestion

    Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  30. Pharmacodynamics - Area under the concentration-time curve - AUCglucagon, 0-240min (optional)

    AUCglucagon,0-240min, area under the glucagon concentration-time curve from 0 to 240 min post-ingestion

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  31. Pharmacodynamics - Free fatty acids concentration-time curves

    Free fatty acids concentration-time curves following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  32. Pharmacodynamics - Maximum free fatty acids concentration - Cmax

    Cmax, Maximum free fatty acids concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  33. Pharmacodynamics - Time to maximum free fatty acids concentration - Tmax

    Tmax, Time to maximum free fatty acids concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  34. Pharmacodynamics - Area under the concentration-time curve - AUCfree fatty acids, 0-60min

    AUCfree fatty acids,0-60min, area under the free fatty acids concentration-time curve

    Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  35. Pharmacodynamics - Area under the concentration-time curve - AUCfree fatty acids, 0-240min

    AUCfree fatty acids,0-240min, area under the free fatty acids concentration-time curve

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  36. Pharmacodynamics - Triglycerides concentration-time curves

    Triglycerides concentration-time curves following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  37. Pharmacodynamics - Maximum triglycerides concentration - Cmax

    Cmax, Maximum triglycerides concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  38. Pharmacodynamics - Time to maximum triglycerides concentration - Tmax

    Tmax, Time to maximum triglycerides concentration following ingestion of mixed meal test and acetaminophen

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  39. Pharmacodynamics - Area under the concentration-time curve - AUCtriglycerides, 0-60min

    AUCtriglycerides,0-60min, area under the triglycerides concentration-time

    Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  40. Pharmacodynamics - Area under the concentration-time curve - AUCtriglycerides,0-240min

    AUCtriglycerides,0-240min, area under the triglycerides concentration-time curve

    Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose

  41. Anti-ZP7570 antibodies - Incidence and titres

    Overall anti-ZP7570 antibody incidence and titers. Incidence of anti-ZP7570 antibodies cross-reacting with endogenous GLP-1 or GLP-2.

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  42. Safety Lab - Haematological values vs. reference ranges and baseline

    Abnormal values or changes in haematology.

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  43. Safety Lab - Clinical chemistry values vs. reference ranges and baseline

    Abnormal values or changes in chemical chemistry

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  44. Safety Lab - Urinalysis values vs. reference ranges and baseline

    Abnormal values or changes in urinalysis

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  45. Safety - Vital signs: blood pressure

    Changes in diastolic and systolic blood pressure (in mmHg)

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  46. Safety - Vital signs: pulse

    Changes in pulse (beats per minute)

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  47. Safety - Physical Examination

    Changes in physical examination of the body. Outcome will be measured as 'normal' or 'abnormal', if abnormal as 'not clinically significant' or 'clinically significant'.

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  48. Safety - ECG

    Changes or abnormalities in ECG parameters (in ms): Heart rate, PR, QRS, QT, QTcF

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

  49. Safety - Injection site reactions

    Occurrence of injection site reactions

    Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, North Rhine-Westphalia 41460, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Aug 2021, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2020
First posted
Nov 3, 2020
StartActual
Oct 26, 2020
Primary completionActual
Aug 30, 2021
CompletionActual
Aug 30, 2021
Last update
Sep 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04612517
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Nov 3, 2020
Start date
Oct 26, 2020
Primary completion
Aug 30, 2021
Completion
Aug 30, 2021
Last update
Sep 2, 2021

Study contacts

Ulrike Hövelmann
principal investigator · Profil Institut für Stoffwechselforschung GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapiglutide

Start the discussion